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Abstract In order to identify the function of deafness locus
putative guanine nucleotide exchange factor (DelGEF), a pro-
tein homologous to the nucleotide exchange factor for the small
GTPase Ran, a cDNA library was screened for interacting
proteins using a yeast two-hybrid system. The human homo-
logue of Sec5, a protein involved in vesicle transport and secre-
tion, was identi¢ed as a binding partner. The interaction be-
tween DelGEF and Sec5 was found to be dependent on Mg2+
and stimulated by guanosine triphosphate (GTP) or deoxycyti-
dine triphosphate (dCTP). Downregulation of endogenous Del-
GEF in HeLa cells induced increased extracellular secretion of
proteoglycans indicating a possible role for DelGEF in the se-
cretion process.
/ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The DelGEF (deafness locus-associated putative guanine
nucleotide exchange factor) protein [1] is a homologue of
RanGEF, the guanine nucleotide exchange factor for the
small GTPase Ran [2]. DelGEF is a ubiquitously expressed
and soluble protein with a size of 49 kDa. A structural motif
consisting of seven internal repeats is found in RanGEF and
de¢nes the three-dimensional structure of RanGEF which re-
sembles a seven-bladed propeller [3,4]. A similar repeat struc-
ture, in which structurally important residues are conserved, is
found in DelGEF suggesting that DelGEF may adopt a sim-
ilar tertiary structure as RanGEF. The gene encoding Del-
GEF is located at a 225 kb genomic sequence of chromosome
11p14, critical for DFNB18, a locus for non-syndromic senso-
rineural deafness [5].
In the present study we aimed at identifying proteins inter-
acting with DelGEF, using the yeast two-hybrid system. Del-
GEF was found to bind to the human homologue of Sec5, a
subunit of the sec6/8 multiprotein complex. Binding was de-
tected in the presence of Mg2þ and could be signi¢cantly
stimulated by addition of guanosine triphosphate (GTP) or
deoxycytidine triphosphate (dCTP). Furthermore, downregu-
lation of endogenous DelGEF in HeLa cells using antisense
oligonucleotides induced extracellular secretion of proteogly-
cans, indicating a possible role for DelGEF in the secretion
process.
2. Materials and methods
2.1. Yeast two-hybrid selection
The complete open reading frame of human DelGEF1 was cloned
into the vector pGBT9 (Clontech) in frame with a Gal4 binding
domain. Saccharomyces cerevisiae strains Y187 (MATK, ura3^52,
his3^200, ade2^101, trp1^901, leu2^3112, gal4v, met3, gal80v,
URA3: :GAL1UAS-GAL1TATA-lacZ) and PJ69-4A (MATa, trp1^901,
leu2^3112, ura3^52, his3^200, gal4v, gal80v, GAL2-ADE2, LYS2: :
GAL1-HIS3, met2: :GAL7-lacZ) were transformed with the bait
plasmid and with a human T-cell lymphocyte cDNA library fused
to the Gal4 activating domain in the vector pACT2 (Clontech), re-
spectively. The transformed strains were mated on nitrocellulose ¢l-
ters. Transformants were grown on selection plates lacking leucine,
tryptophan, histidine and adenine. Plasmids were recovered from
growing colonies and ampli¢ed through Escherichia coli transforma-
tion. Recovered plasmids encoding potential interactors were cotrans-
formed with bait plasmid into yeast strain Y190 (MATa, ura3^52,
his3^200, lys2^801, ade2^101, trp1^901, leu2^3112, gal80v, cyhr,
LYS: :GAL1UAS-HIS3tata-HIS3, URA3: :GAL1UAS-GAL1TATA-lacZ)
to con¢rm the Tryþ Hisþ LacZþ phenotype. Cotransformation with
pGBT9 (without insert) was done as negative control to verify speci¢c
interaction.
2.2. Rapid ampli¢cation of complementary deoxyribonucleic acid
ends-polymerase chain reaction (RACE-PCR)
RACE-PCR primers were designed based on the human sec5 se-
quence obtained in the yeast two-hybrid screening as follows (5P-
GCTGCCCTCACTCTTCTTGTTAGCC-3P, 5P-CCTTCATTTGGA-
GAGATGCCGGTCA-3P). RACE-PCR was performed according to
manufacturers instructions using the Marathon cDNA ampli¢cation
kit (Clontech). A human brain RACE-ready cDNA library (Clontech)
was used as template.
2.3. Expression of DelGEF-glutathione S-transferase (GST) fusion
protein
Full-length DelGEF cDNA was cloned into the vector pGEX-4T-2
(Amersham Pharmacia Biotech) allowing the expression of a fusion
protein with an N-terminal GST domain and a C-terminal DelGEF
domain. Bacterial expression of DelGEF-GST was done as described
previously [1] and the fusion protein was puri¢ed by glutathione Seph-
arose 4B a⁄nity chromatography (Amersham Pharmacia Biotech) ac-
cording to manufacturers instructions.
2.4. In vitro binding assay
A cDNA containing the full-length coding sequence of human Sec5
with an additional T7 promotor sequence was ampli¢ed by PCR
(upper primer: 5P-TAATACGACTCACTA TAGGGAGACCAC-
ATGTCTCGA-3P, lower primer: 5P-TCAATATGTGCCACGCCAT
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TCC-3P) from a human brain cDNA library (Clontech). A cDNA
corresponding to the C-terminal DelGEF binding domain (amino
acid residues 447^924) of human Sec5 with an additional T7 promotor
sequence was ampli¢ed by PCR (upper primer: 5P-AAAATTG TAA-
TACGACTCACTATAGGGCGACCACCA AACCCAAAAAAAG-
AG-3P, lower primer: 5P-ACTTGCGGGGTTTTTCAGTATCTA-
CGAT-3P) from a pACT2 plasmid containing the DelGEF cDNA.
These cDNAs were used as templates for coupled in vitro transcrip-
tion and translation using the TnT Coupled Reticulocyte Lysate
System (Promega). Sec5 was radiolabelled by incorporation of
[35S]methionine (Amersham Pharmacia Biotech) during the transla-
tion reaction. 0.2 mg of DelGEF-GST or GST alone was immobilised
on 10 Wl glutathione Sepharose 4B beads (Amersham Pharmacia Bio-
tech). 5 Wl of the Sec5 transcription/translation reaction was added to
the beads and incubated for 1 h at 25‡C in 500 Wl binding bu¡er (20
mM Tris^HCl, pH 8.0, 100 mM NaCl and 0.1% Triton X-100) sup-
plemented with ethylenediamine tetraacetic acid (EDTA), MgCl2,
CaCl2, MnSO4 or nucleotide as indicated in the text. The beads
were extensively washed in binding bu¡er. Bound proteins were eluted
in electrophoresis sample bu¡er by heating at 95‡C for 5 min and
separated by sodium dodecyl sulphate^polyacrylamide gel electropho-
resis (SDS^PAGE). The gel was incubated with 1 M sodium salicylate
(pH 6.0) for 15 min, dried and exposed to Biomax MR ¢lm for 12 h.
Computerised images of £uorographs were used for determination of
band intensities using the NIH Image software.
2.5. Northern blot analysis
A cDNA corresponding to nucleotides 1370^2815 of human sec5
was ampli¢ed by PCR and used as template in an oligo-labelling
reaction using the NonaPrimer kit (Appligene). The 32P-labelled probe
was hybridised to human multiple tissue Northern blots (Clontech)
according to manufacturers instructions. Exposure was for 72 h using
X-OMAT AR ¢lm (Kodak).
2.6. Antisense oligonucleotide treatment
HeLa (human cervix carcinoma epithelial) cells (ATCC#CCL-2)
were maintained under standard conditions. For antisense treatment,
cells were plated at 50 000/ml and incubated for 4 h to allow attach-
ment. To a solution containing 100 WM antisense or scrambled oligo-
nucleotide was added 5 vol. Dulbecco’s modi¢ed Eagle’s medium
(DMEM) and 0.25 vol. Superfect transfection reagent (Qiagen). The
solution was incubated at 25‡C for 10 min and added to the cells at a
¢nal concentration of 500 nM oligonucleotide. After 24 h cells were
used for analysis of DelGEF expression or proteoglycan release. The
following phosphorothioate-modi¢ed oligonucleotides (MWG Bio-
tech) were used: DG1 (5P-GCTCGCGCTCCATGC-3P), DG2 (5P-
TATTCCCTACTCTCTGAC-3P), DG3 (5P-GTTCTCTTCACCCAC-
CATTA-3P). Corresponding scrambled control oligonucleotides were
synthesised as follows: DG1ctrl (5P-CGTACCTCGCGCTCG-3P),
DG2ctrl (5P-CAGTCTCTCATCCCTTAT-3P), DG3ctrl (5P-ATTAC-
CACCCACTTCTCTTG-3P).
2.7. RNA isolation and quantitative reverse transcriptase (RT)-PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen) and
quantitated by spectrophotometric measurements. 0.5 Wg of RNA was
used for ¢rst-strand cDNA synthesis using superscript II reverse tran-
scriptase (Life Technologies). The cDNA was used as template for
PCR using DelGEF-speci¢c primers (upstream: 5P-TGGGATTT-
TACGATTATGCTCA-3P, downstream: 5P-GCACAACCGTCGTC-
CAC-3P). As RNA quality control, PCR was performed with primers
speci¢c for 18S ribosomal RNA using the QuantumRNA Classic 18S
primer set (Ambion). PCR products from reactions in linear phase
(22^24 cycles) were quantitated on an Agilent 2100 Bioanalyzer using
the DNA 7500 LabChip kit (Agilent Technologies).
2.8. Labelling and detection of secreted proteoglycans
Cells were incubated with 0.1 mCi/ml of 35SO4 (Amersham Phar-
macia Biotech) in labelling bu¡er (20 mM HEPES, 125 mM NaCl,
5 mM KCl, 1.8 mM CaCl2, 1.8 mM MgCl2, 5.6 mM glucose, pH 7.2)
for 30 min. The labelling bu¡er was removed and cells were incubated
in complete medium for 1^3 h. The medium was removed and brie£y
centrifuged to remove detached cells. Four vol. of acetone were added
to the medium and protein precipitation was allowed to proceed over-
night at 320‡C. Proteins were pelleted by centrifugation (10 000Ug,
20 min), resuspended in SDS loading bu¡er and resolved by SDS^
PAGE. The gel was incubated with 1 M salicylate (pH 6.0) for 30
min, dried and exposed to Biomax MR ¢lm (Kodak). Computerised
images of the £uorographs were obtained by scanning, allowing for
determination of band intensities using the NIH Image software.
3. Results
3.1. Identi¢cation of Sec5 as a protein interacting with DelGEF
In order to identify proteins interacting with DelGEF, a
human cDNA library was screened using a yeast two-hybrid
system. Of an estimated 4U106 transformants screened, 60
clones expressing reporter activity (L-galactosidase) could be
identi¢ed and prey constructs were recovered from these col-
onies. The isolated plasmids were sequenced and the cDNAs
from these clones were compared with nucleotide sequences of
known proteins using the BLASTN algorithm. Two human
cDNA sequences encoding potential DelGEF binding part-
ners were obtained, one of these was found to be a human
homologue of Sec5. The speci¢c interaction between the
pGBT9-DelGEF bait plasmid and the isolated pACT2 plas-
mid carrying the Sec5 cDNA was veri¢ed by cotransforma-
tion. Only upon cotransformation with pGBT9-DelGEF and
not with pGBT9 (without insert) did the yeast colonies display
reporter activity (not shown). Transformation with pGBT9-
DelGEF alone did not induce reporter activity (not shown).
The human Sec5 sequence obtained in the yeast two-hybrid
screening was 95% identical to the C-terminal region (amino
acid residues 447^924) of rat Sec5 [6] (GenBank acc. no.
AF032666) indicating that DelGEF interacts with the C-ter-
minal region of human Sec5. By using RACE-PCR, addition-
al sequence information was obtained (not shown) yielding
the complete coding sequence of human sec5 (deposited in
the EMBL database, acc. no. AJ414403). The open reading
frame consists of 2772 nucleotides encoding a protein of 924
amino acid residues (Fig. 1). The complete human Sec5
sequence was found to be 94% identical with rat Sec5 at
the amino acid level. A nucleotide binding motif (A/
G,X,X,X,X,G,K,S/T) [7] was identi¢ed in close proximity to
Fig. 1. Amino acid sequence of a human homologue of Sec5. The
complete sequence of human Sec5 was obtained by yeast two-hybrid
interaction cloning and subsequent RACE-PCR. The sequence has
been deposited in the EMBL database (acc. no. AJ414403). The
C-terminal region of human Sec5 interacting with DelGEF is under-
lined. A putative nucleotide binding site is boxed.
FEBS 26783 19-11-02
M. Sjo«linder et al./FEBS Letters 532 (2002) 211^215212
the domain interacting with DelGEF in the yeast two-hybrid
system (Fig. 1).
The second cDNA sequence obtained in the yeast two-hy-
brid screening encodes a protein which displays no signi¢cant
homology to other proteins and has not been described in the
literature. It is currently being characterised in our laboratory.
3.2. Sec5 mRNA tissue distribution
The tissue distribution of human Sec5 was investigated by
Northern blot analysis (Fig. 2). A radiolabelled probe was
prepared and hybridised to a human multiple tissue RNA
blot. The predominantly expressed mRNA was found to
have a size of around 4.5 kb. This transcript was detectable
in all tissues and was highly expressed in brain and placenta.
In addition, shorter transcripts could be observed. A tran-
script of approximately 1.5 kb was strongly expressed in skel-
etal muscle.
3.3. E¡ects of metal ions and nucleotides on the DelGEF/Sec5
interaction
In order to verify the interaction between DelGEF and
Sec5, in vitro binding experiments were performed. Recombi-
nant GST-tagged DelGEF was bound to glutathione Sepha-
rose beads. 35S-labelled Sec5, obtained by coupled in vitro
transcription/translation, was incubated with the beads. Fi-
nally, the material binding to the beads was analysed by gel
electrophoresis. It was found that radiolabelled Sec5 could
bind to DelGEF-GST coated beads only in the presence of
1 mM Mg2þ or 1 mM Mn2þ (Fig. 3). Binding could not be
detected in the presence of 1 mM Ca2þ or 1 mM EDTA.
Beads coated with GST alone did not retain Sec5, indepen-
dent of bu¡er conditions.
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Fig. 2. Expression of sec5 mRNA in human tissues. A 32P-labelled
cDNA probe speci¢c for human sec5 was hybridised to human mul-
tiple tissue RNA blots. RNA size markers are indicated.
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Fig. 4. In vitro binding between DelGEF and Sec5 in the presence
of nucleotides. Recombinant DelGEF-GST was immobilised on glu-
tathione Sepharose beads and incubated with 35S-labelled full-length
or truncated Sec5 produced by coupled in vitro transcription and
translation. The binding bu¡er (20 mM Tris^HCl, pH 8.0, 100 mM
NaCl, 1 mM Mg2þ and 0.1% Triton X-100) was supplemented with
nucleotide as indicated. Radiolabelled material binding to the beads
was detected by SDS^PAGE and subsequent £uorography. Binding
was estimated by measuring band intensities using the NIH Image
software. Values indicate meansWS.D. of four experiments.
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Since human Sec5 was found to contain a nucleotide bind-
ing motif and since DelGEF is a homologue of RanGEF [2],
we investigated if the addition of nucleotides to the in vitro
binding reaction could a¡ect the binding between DelGEF
and Sec5 (Fig. 4). All binding reactions were performed in
the presence of 1 mM Mg2þ. Addition of dCTP (500 WM)
or GTP (500 WM) stimulated the interaction leading to an
approximately 10- or three-fold increase of Sec5 binding to
DelGEF, respectively. Other nucleotide triphosphates (ATP,
CTP, TTP, dATP, dGTP and dTTP) and the nucleotide di-
phosphates (GDP and dCDP) did not signi¢cantly alter the
amount of Sec5 binding to immobilised DelGEF at 500 WM
nucleotide concentration. At 100 WM dCTP there was a ¢ve-
fold stimulation of complex formation whereas 1 and 10 WM
dCTP were without e¡ect. When using a truncated Sec5 pro-
tein (residues 447^924) containing only the DelGEF binding
domain indicated in Fig. 1, and not the putative nucleotide
binding domain, there was no stimulation of complex forma-
tion by 500 WM dCTP or 500 WM GTP (Fig. 4).
3.4. E¡ect of endogenous DelGEF downregulation on
proteoglycan secretion
The interaction between DelGEF and Sec5 prompted us to
investigate the role of DelGEF in secretion. We attempted to
downregulate the expression of endogenous DelGEF in cul-
tured human cells by antisense oligonucleotide treatment. A
set of phosphorothioate-modi¢ed oligonucleotides were tested
for their ability to lower the levels of DelGEF mRNA in
HeLa cells. Two antisense oligonucleotides, DG2 and DG3,
were found to induce downregulation of DelGEF mRNA
(Fig. 5A). Double-stranded RNA oligonucleotides were re-
cently shown to mediate gene silencing [8] but we could not
detect DelGEF mRNA downregulation when transfecting
with DelGEF-speci¢c RNA duplexes (not shown).
The secretion of sulphated proteoglycans is a commonly
used £uid phase marker of constitutive secretion [9^12]. In
HeLa cells, chondroitin sulphate proteoglycans are the pre-
dominant proteoglycan species released upon sulphate label-
ling [13]. The expression of DelGEF in HeLa cells was down-
regulated by treatment with antisense oligonucleotide DG3.
Thereafter the extracellular release of 35SO4-labelled sulphated
proteoglycans was determined (Fig. 5B). The release of sulph-
ated proteoglycans was complete after 2 h in both control and
antisense-treated cells. Sulfated proteoglycan release was
found to increase two-fold in cells subjected to DelGEF anti-
sense treatment. In contrast, there was no e¡ect of the anti-
sense treatment on cell growth and cell viability as judged by
proliferation assays and trypan blue exclusion (not shown).
The total (intracellular+extracellular) levels of labelled proteo-
glycans were not signi¢cantly changed upon antisense treat-
ment indicating that proteoglycan synthesis was not altered by
DelGEF downregulation (not shown).
4. Discussion
Using the yeast two-hybrid system, a human cDNA library
was screened for proteins capable of interacting with DelGEF.
We found that DelGEF interacts with a human homologue of
Sec5, a protein involved in secretion. Sec5 is a component of
the Sec6/8 multiprotein complex [14,15], the mammalian
counterpart of the yeast exocyst complex [16^18]. The Sec6/
8 complex is required for secretion and provides a mechanism
for targeting secretory vesicles to sites of plasma membrane
fusion [19,20]. We have determined the complete coding se-
quence of human Sec5 (Fig. 1) and found it to be 94% iden-
tical to rat Sec5 [6] at the amino acid level. Multiple tissue
Northern blot analyses (Fig. 2) indicated that human Sec5 is
ubiquitously expressed.
The interaction between DelGEF and Sec5 was con¢rmed
by in vitro binding experiments and was found to be depen-
dent on addition of Mg2þ or Mn2þ (Fig. 3). In addition, the
binding could be stimulated by the addition of GTP or dCTP,
whereas other ribonucleotides and deoxyribonucleotides were
ine¡ective (Fig. 4). The physiological concentrations of GTP
and dCTP have been estimated to be around 500 and 50 WM,
respectively [21]. We observed signi¢cant stimulation of com-
plex formation at 500 WM GTP and 100 WM dCTP suggesting
that GTP and possibly also dCTP can regulate the DelGEF^
Sec5 interaction in vivo. The results suggest the presence of
nucleotide binding sites within the DelGEF^Sec5 complex. In
accordance, a putative nucleotide binding motif was observed
in close proximity to the DelGEF-interacting domain of hu-
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man Sec5. When using a truncated form of Sec5 without the
putative nucleotide binding site, there was no stimulation of in
vitro binding between DelGEF and Sec5 by GTP or dCTP.
GTP binding proteins are known to regulate many di¡erent
functions in the cell whereas dCTP functions mainly as a
substrate for enzymes involved in nucleotide metabolism,
DNA synthesis and DNA repair. The exact mechanisms
whereby GTP and dCTP stimulate formation of the Del-
GEF^Sec5 complex will require further investigation. For ex-
ample, dCTP may stabilise the DelGEF^Sec5 complex by
replacing another nucleotide normally promoting a hydroly-
sis-associated interaction of transient character. In the case of
the enzyme aspartate transcarbamoylase, dCTP functions as a
competitive inhibitor of ATP-dependent activation [22].
Since DelGEF interacts with Sec5, we investigated whether
DelGEF plays a functional role in secretion. Using antisense
oligonucleotides, the expression of endogenous DelGEF could
be selectively downregulated in HeLa cells (Fig. 5). Subse-
quently, the extracellular secretion of chondroitin sulphate
proteoglycans was measured. The extracellular release of pro-
teoglycans is a commonly used £uid phase marker of consti-
tutive secretion [10,11]. Upon inhibition of DelGEF expres-
sion, secretion of chondroitin sulphate proteoglycans was
signi¢cantly upregulated, indicating a regulatory function for
endogenously expressed DelGEF in the secretion process. In
contrast, total synthesis of chondroitin sulphate proteoglycans
was not signi¢cantly a¡ected by DelGEF antisense treatment,
indicating that proteoglycan synthesis was not a¡ected by
downregulation of endogenous DelGEF.
Ongoing work in our laboratory is aimed at studying the
mechanism whereby GTP and dCTP regulate formation of the
DelGEF^Sec5 complex and to de¢ne the cellular role of Del-
GEF in the secretion process.
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